Arthritis Advisory Committee members saw a lifeline to deal with extrapolation concerns for Celltrion Inc.'s biosimilar Inflectra in an ongoing trial in inflammatory bowel disease.
However, FDA said simply hoping for reassurance by waiting for additional clinical data is not the purpose of the abbreviated biosimilar pathway.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?